Surgical treatment and prognosis is different in esophageal, cardiac and distal gastric adenocarcinomas. Determination of the origin, in particular of adenocarcinomas situated at the gastroesophageal junction, may be difficult. It has been suggested that esophageal adenocarcinomas are characterized by a specific cytokeratin pattern, namely the CK7 þ /CK20À pattern. According to the same authors, this cytokeratin pattern is absent in gastric adenocarcinomas. The aim of our study is to evaluate if this cytokeratin pattern CK7 þ /CK20À is absent in cardiac and distal gastric adenocarcinomas. Therefore, we evaluated the combined immunohistochemical expression of CK7 and CK20 on paraffin-embedded material of 214 resection specimens for adenocarcinoma, comprising 66 esophageal, 73 cardiac and 75 distal gastric adenocarcinomas (UICC-classification). The adenocarcinomas were subtyped into intestinal-and diffuse-type according to the Lauren classification. The immunohistochemical staining was considered as positive if 50% or more of the tumor cells were stained. Statistical analysis has been performed applying the v 2 -test. The tumors situated at the gastroesophageal junction, esophageal as well as cardiac adenocarcinomas, showed predominantly a CK7 þ /CK20À expression pattern (67 vs 68%), whereas this cytokeratin pattern is rather uncommon in distal gastric adenocarcinomas (31%, Po4 Â 10 À5 ). Independent of their localization, intestinal-as well as diffuse-type adenocarcinomas have a similar cytokeratin pattern. Our data show that the combined expression of CK7 and CK20 is different for the adenocarcinomas situated on both sides of the gastroesophageal junction compared to the distal gastric adenocarcinomas. However, in contrast to data in the literature, the combined expression of CK7 and CK20 has a low specificity in the distinction between esophageal and cardiac adenocarcinomas. This may suggest a similar origin (cell lineage) and thus may have an impact on therapeutic strategies.
Epidemiological studies have shown that the topographical distribution of gastric cancer is changing. Tumors become more prevalent in the cardia, whereas the incidence of gastric cancer confined to the distal part of the stomach decreases. 1, 2 During the last few decades the annual age-adjusted incidence of cardiac adenocarcinomas has increased by 4-5%. 3 This rise in incidence occurs in parallel with the increase in incidence of esophageal adenocarcinomas. In white male subjects, the ageadjusted incidence rates of this cancer increased from 0.7 during 1974-1976 to 3.2 during 1992-1994. 2 The epidemiological study of El-Serag et al 4 suggests that these tumors are two distinct entities: the increase in incidence of esophageal and cardiac adenocarcinomas is both related to age, but only in esophageal adenocarcinomas a cohort effect is observed. Although the prognosis of esophageal adenocarcinomas is poor, cardiac adenocarcinomas have an even worse prognosis, due to an advanced stage of disease and the presence of lymph node metastasis at the time of diagnosis. [5] [6] [7] [8] The localization of the tumor, and also the different dissemination pattern to the lymph nodes will determine the choice of treatment. There is still some debate about the type and the extent of surgical treatment. To improve the survival of patients, the need for a wide peritumoral dissection, including the removal of peritumoral tissue in the mediastinum, is adviced. Extended lymphadenectomy may improve the overall survival. 9, 10 Moreover, different precursors may be involved in the histogenesis of esophageal adenocarcinomas and cardiac adenocarcinomas. In the first type, the relationship with Barrett's esophagus is wellknown. The development of a Barrett's esophagus is the result of a longstanding reflux of acid and bile. 11, 12 The etiopathogenesis of cardiac adenocarcinomas is less clear. Carditis and intestinal metaplasia are proposed as precursor lesions for this cancer. Several studies identified a relationship between carditis and gastroesophageal reflux. 13, 14 According to other studies, however, carditis was an extension of a Helicobacter pylori-related pangastritis. 15, 16 Based on these epidemiological and etiopathological data, distal esophageal and cardiac adenocarcinomas would seem to be two distinct entities. However, both adenocarcinomas mostly present in an advanced stage of disease, as a result of which, the origin of these tumors is difficult to determine. According to Ormsby et al, 17 Barrett's related esophageal adenocarcinomas are characterized by a specific cytokeratin pattern, namely the CK7 þ / CK20À expression pattern. This pattern would seem to be confined to this type of tumor and its precursor, when compared to gastric cancer. However, the number of gastric adenocarcinomas (n ¼ 14) investigated in their study was limited. Furthermore, these gastric tumors originated from the subcardia and by definition not cardia, as only these tumors were included of which the most proximal part of the tumor was situated at a minimum distance of 35 mm of the gastroesophageal junction. Moreover, they only studied intestinaltype of adenocarcinomas.
Therefore, we performed a similar study on a larger number of cases, originating from the esophagus, cardia and distal stomach, divided into intestinal-and diffuse-type using the same methodology. The aim of our study was to evaluate whether this CK7 þ /CK20À pattern was confined to esophageal adenocarcinomas.
Materials and methods
We have reviewed 214 adenocarcinomas of the esophagus, the cardia or the distal stomach (Table 1) . Adenocarcinomas situated at the gastroesophageal junction were classified into esophageal or cardiac adenocarcinomas according to recommendations of the International Union Against Cancer (UICC). The major criteria for the distinction between gastric cardia and distal esophagus were the localization of the bulk of the tumor and the presence of an associated Barrett's esophagus. If more than 50% of the mass of the tumor was situated in the cardia, the tumor was classified as being of cardiac origin, whereas if the mass of the tumor was predominantly found in the esophagus, the UICC advises to classify it as an esophageal tumor. According to these advices, a tumor situated on the gastroesophageal junction was likely to be of esophageal origin when the neoplastic lesion was associated with a Barrett's esophagus of the specialized or intestinal type. 18 The presence of a Barrett's esophagus was evaluated on biopsies taken above the gastro-esophageal junction, either during endoscopic examinations prior to surgery, and/or from the resection specimen. Barrett's esophagus was defined by the presence of intestinal type of columnar epithelium independent of the length of the lesion. 19 Distal gastric tumors were situated in the corpus and/or the antrum of the stomach.
Routine histology was performed on samples of the resection specimen, fixed in formaldehyde and embedded in paraffin. In accordance with the Lauren classification, the tumors were classified into diffuse-or intestinal-type of adenocarcinomas, based on their histopathological features. Tumors demonstrating mixed histological features were classified according their predominant features. 20 In order to evaluate the presence of goblet cells in the epithelium of a Barrett's esophagus, an alcian blue/PAS staining (pH 2.5) was performed. This stain allows distinction between gastric (red) and intestinal type (blue) of mucins. 21 Immunohistochemistry was performed on one tissue block, representative of the tumor mass in the resection specimen. For immunohistochemical analysis, we used a CK7Àantibody (Dako, Denmark, monoclonal antibody, clone OV-TL 12/30, dilution 1/50) and a CK20Àantibody (Dako, Denmark, monoclonal antibody, clone Ks20.8, dilution 1/50), on semiserial sections of the paraffin-embedded, formol-fixed material. The staining carried out using an avidin-biotin method with antigen retrieval. The staining was performed on an automated Ventana IHC instrument, using the Ventana basic DAB detection kit. Our immunohistochemical analysis was validated through positive and negative controls (by omitting the primary antibody). In accordance with the criteria of Ormsby et al Cytokeratins in GE junction tumors A Driessen et al a tumor was considered to be positive for CK7 or CK20 if 50% or more of the tumor cells showed a predominantly intense cytoplasmic positivity for this cytokeratin. For statistical analysis, we used the w 2 -test, in which Po0.05 was considered to be statistically significant. The sensitivity, the specificity and the positive predictive value were determined according to the Bayes theorem.
Results

Clinical Data of the Patients
The series of 214 patients, was composed of 66 patients, having a distal esophageal adenocarcinoma, 73 patients with a cardiac carcinoma and 75 patients with a distal gastric cancer. The mean age of the overall population was 66 years (range 32-90 years). Table 1 presents the clinical characteristics of all patients included in this study. Whereas the group of esophageal and cardiac carcinomas have a comparable age distribution, the group of patients, having a distal gastric cancer, consists of elderly people. In this group, there is no significant gender predominance, whereas the groups of esophageal adenocarcinomas (Po0.003) and cardiac adenocarcinomas (Po0.05) are both mainly composed of males.
Immunohistochemical Analysis in Function of the Localization of the Adenocarcinomas (Figure 1)
Immunohistochemical analysis revealed a heterogeneous combined expression pattern of CK7 and CK20. The overall prevalence of CK7Àpositivity was 66% (n ¼ 142/214) with the following distribution pattern: esophageal adenocarcinomas 82% (n ¼ 54/ 66), cardiac adenocarcinomas 77% (n ¼ 57/73) and distal gastric adenocarcinomas 39% (n ¼ 31/75). There was a significant lower prevalence in distal gastric carcinomas than in esophageal (P ¼ 2 Â 10 À6 ) and cardiac carcinomas (P ¼ 1 Â 10 À5 ). CK20 immunoreactivity was present in 18% of the whole population (n ¼ 38/214). The distribution of CK20Àpositivity in function of the location of the tumor did not vary significantly: esophageal adenocarcinomas 21% (n ¼ 14/66), cardiac adenocarcinomas 13% (n ¼ 10/73) and distal gastric adenocarcinomas 20% (n ¼ 15/75). Esophageal and cardiac adenocarcinomas were mostly characterized by a presence of CK7, combined with an absence of CK20 (Figures 2 and 3) . The prevalence of this CK7 þ /CK20À pattern is comparable in esophageal (67%, n ¼ 44/66) and cardiac adenocarcinomas (68%, n ¼ 50/73) and is significantly higher than in distal gastric adenocarcinomas (31%, n ¼ 23/75) (P ¼ 9 Â 10 À6 vs P ¼ 4 Â 10 À5 ). The sensitivity, the specificity and the positive predictive value of this cytokeratin pattern for esophageal adenocarcinomas was 67, 51 and 38%, respectively, which was comparable to those for cardiac adenocarcinomas, namely 68, 52 and 43%, respectively. In contrast, nearly half of the distal gastric adenocarcinomas did not express CK7 or CK20 (49%, n ¼ 37/75). This CK7À/CK20À pattern was only observed in 12% of the esophageal adenocarcinomas (n ¼ 8/66) (P ¼ 5 Â 10 À6 ) and in 18% of the cardiac adenocarcinomas (n ¼ 13/73) (P ¼ 1 Â 10 À4 ). Although the sensitivity of this cytokeratin pattern for distal gastric carcinomas is low, namely 49%, it has a high specificity, namely 81% and a moderately high positive predictive value, namely 64%.
The frequency of the other cytokeratin patterns, namely CK7 þ /CK20 þ or CK7À/CK20 þ , was independent of the localization of the adenocarcinomas.
Immunohistochemical Analysis in Function of the Type of Adenocarcinomas, Subtyped According to the Lauren Classification (Figure 4) Analysis of the morphological features of the tumors showed that our population of adenocarcinomas consisted predominantly of intestinal-type of tumors (68%, n ¼ 145/214), namely in the esophagus (n ¼ 79%, 52/66), the cardia (73%, n ¼ 53/73) and less so in the distal stomach (53%, n ¼ 40/75). The overall prevalence of diffuse-type adenocarcinomas was 32% with the following distribution pattern: esophagus 21%, cardia 27% and distal stomach 47%.
A diffuse cytoplasmatic positivity for CK7 was overall diagnosed in 66% (n ¼ 142/214) with a nearly significant higher prevalence in intestinaltype adenocarcinomas 70% (n ¼ 101/145) than in diffuse-type adenocarcinomas 55% (n ¼ 38/69) (P ¼ 0.053). CK20Àpositivity was present in a limited number of intestinal-(19%, n ¼ 27/145) and diffuse-type adenocarcinomas (18%, n ¼ 12/69). There was no difference in coexpression of CK7 and CK20 in intestinal-and diffuse-type adenocarcinomas. The CK7 þ /CK20À pattern was observed in 57% of the intestinal-type adenocarcinomas (n ¼ 83/145) and 55% of the diffuse-type adenocarcinomas (n ¼ 32/69), whereas the CK7À,CK20À 
Discussion
Immunohistochemistry is currently routinely applied in the diagnosis of human cancer. Antibodies directed against cytokeratins, which are intermediate filament proteins, can establish the epithelial cell lineage of neoplastic cells. Cytokeratins are composed of tetrameric heteropolymers of two different keratins, belonging to the family of acidic (type I) and basic (type II) keratins. 22 Certain cytokeratins have a restricted tissue distribution. Therefore, they can be used to identify certain subtypes of carcinomas. CK7, a type II cytokeratin with a molecular weight of 54 kDa, is strongly expressed in normal tissues such as the transitional cell epithelium of the bladder and the ducts of the pancreatico-biliary system. In function of the applied clone (OV-TL 12/30) the surface epithelium of the stomach can also express CK7.
23 CK20, a type I cytokeratin with a molecular weight of 46 kDa, has a limited expression pattern virtually confined to the gastrointestinal tract. 24, 25 In the stomach, the CK20Àpositivity is situated in the upper part of the gastric pits. 26 As CK20 is expressed throughout the whole gastro-intestinal tract, it is less useful than CK7, in order to distinguish metastasis of adenocarcinomas originating from different parts of the gastrointestinal tract. 26 However the combined expression of both cytokeratins may solve this problem, as for example, metastases of colonic adenocarcinomas are negative for CK7 and positive for CK20, whereas the opposite is true for adenocarcinomas of the pancreas or biliary tract. 27 In our study, we aimed to analyze the coexpression of CK7 and CK20 on three different tumor groups: esophageal, cardiac and distal gastric adenocarcinomas. In accordance with the study of Ormsby et al, 17 we observed that the CK7 þ /CK20À pattern was significantly more prevalent in esophageal adenocarcinomas, than in distal gastric carcinomas, resulting in a comparable specificity (79 vs 69%). Based on their study, Ormsby et al 17 concluded that this cytokeratin pattern is confined to esophageal adenocarcinomas. In our study, we included cardiac adenocarcinomas. Immunohistochemical analysis showed that the CK7 þ /CK20À cytokeratin pattern was not specific for esophageal adenocarcinomas, as the prevalence was similar in cardiac adenocarcinomas. This resulted in a low specificity of this CK7 þ /CK20À pattern in the distinction between these two types of adenocarcinomas of the gastroesophageal junction, namely 31%. Based on this cytokeratin pattern, it was only possible to make a distinction between adenocarcinomas of the gastroesophageal junction vs distal gastric adenocarcinomas. However, this rarely poses a problem as the origin of the tumor can be determined based on the localization of the tumor.
Our data, however, are in contrast with the recently published study of Taniere et al, 28 who showed that esophageal adenocarcinomas have a distinct cytokeratin pattern, different from cardiac adenocarcinomas. 28 The CK7 þ /CK20À was highly specific for esophageal adenocarcinomas (76%). In their study, cardiac adenocarcinomas were characterized by a variable cytokeratin pattern. This discrepancy in results can not be explained by a different immunohistochemical method as the same clones were used, applying an avidin-biotin technique with antigen retrieval. Moreover, the prevalence of the CK7 þ , CK20À pattern in esophageal adenocarcinomas was not significantly different (74 vs 68%) in spite of minor differences in inclusion criteria of distal esophageal adenocarcinomas (Taniere et al and our data) or Barrett adenocarcinomas (Ormsby et al). 17, 28 Another possible explanation is the differences in classification of the adenocarcinomas at the gastroesophageal junction as they subtyped their tumors according to the criteria of Siewert et al. 29 However, when we classified our tumors according to these criteria, the results of our study did not change (data not shown).
Distal gastric adenocarcinomas had a more variable staining pattern. In contrast to the gastroesophageal adenocarcinomas, the CK7À, CK20À pattern is more characteristic for distal gastric adenocarcinomas. Although this pattern is present in only half of the population of distal gastric cancers, this cytokeratin pattern has a high specificity and moderately high sensitivity. These results are in contrast to the study of Ormsby et al 17 in which no predominant staining pattern was found. In the study of Shen et al 30 and Kende et al the majority of distal cancers showed a combined expression of cytokeratin 7 and 20 between 66 and 100%. This prevalence is significantly higher than that in our study population (11%), in which, however, our result is comparable with the data of Taniere et al 28 (12%) and other publications. 17, 31 The histogenetical relationship between intestinal metaplasia and intestinal type of gastric adenocarcinomas and Barrett's adenocarcinomas is wellknown. Recently, Shen et al 30 demonstrated a similar cytokeratin pattern in the gastric cancer and the intestinal metaplasia in the surrounding mucosa. With the exception of one case, their population only consisted of intestinal-type adenocarcinomas. However, we found a similar coexpression of these cytokeratins in intestinaland diffuse-type adenocarcinomas (Figure 4) . Our results confirmed those of Goldstein et al 32 and question the linking of cytokeratin expression to intestinal metaplasia and to cancer.
Our results are in fact a reflection of the published conflicting data on the cytokeratin pattern, found in association with Barrett's esophagus. According to Ormsby et al 33, 34 and Couvelard et al, 35 Barrett's mucosa is characterized by a specific cytokeratin pattern, in which the CK7Àpositivity is situated in the superficial and deep glands of the intestinal metaplasia, whereas only the surface epithelium and superficial glands were positive for CK20. According to these authors, this staining pattern is highly specific for Barrett's esophagus and absent in gastric intestinal metaplasia. However, El-Zimaity and Graham 36 and Glickman et al 37 demonstrated both that this cytokeratin pattern is not restricted to the Barrett's esophagus, but is as frequently present in the intestinal metaplasia of the cardia. Moreover, both studies showed that, be it in a limited number (14-27%), this cytokeratin pattern is present in gastric intestinal metaplasia. These data show similarities with the distribution pattern of cytokeratins in our study population.
In conclusion, although an accurate classification of the gastroesophageal adenocarcinomas is necessary in order to determine the incidence rate of these tumors and to evaluate the success of treatment in function of the chosen therapy, the determination of the origin of the tumor is hampered by the bulk of the tumor. Some studies defined the origin of esophageal adenocarcinomas by showing a unique coexpression of CK7 þ and CK20À, which was absent in gastric tumors. 17, 30 Up to a certain level our study confirm these data. These studies, however, were confined to tumors situated in the distal stomach. In contrast to these studies, we analyzed the expression pattern not only in distal gastric carcinomas but also in cardiac adenocarcinomas. The results of our study showed that the exact origin of tumors, situated at the gastroesophageal junction, as being an esophageal or cardiac tumor, cannot be determined by evaluation the coexpression of CK7 and CK20. Based on this cytokeratin expression pattern, it is not possible to make a distinction between an esophageal or cardiac adenocarcinomas.
